Launched in India in June 2025, Wegovy demonstrated strong clinical efficacy, with about one in three patients losing more than 20% of their body weight during trials
Lengthy authorizations delay treatment
By delaying the entry of nutrients into the small intestine, semaglutide reduces the rapid spikes in blood sugar levels after eating, helping to control hunger and reduce food consumption
Liquid chromatography-tandem mass spectrometry was employed to quantify plasma TMAO, choline and their related metabolites, encompassing TMA, l-carnitine, betaine and dimethylglycine (DMG), which are betaine-related metabolites (Reference Wiedeman, Barr and Green14)
It's intended for adults with obesity, who are overweight, or who have weight-related health conditions